Results 61 to 70 of about 1,782,190 (315)

Rewiring Drug Research and Development through Human Data-Driven Discovery (HD3)

open access: yes, 2023
In an era of unparalleled technical advancement, the pharmaceutical industry is struggling to transform data into increased research and development efficiency, and, as a corollary, new drugs for patients.
Rebecca Racz   +4 more
core   +1 more source

Prognosis of Long‐Term Continuous Renal Replacement Therapy and the Impact of Combined Continuous Intravenous Sodium Infusion Therapy

open access: yesTherapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction Patients requiring long‐term continuous renal replacement therapy (CRRT) generally have poor prognoses. This study evaluated whether adding continuous intravenous sodium infusion (cIVNa) is associated with improved hemodynamics and outcomes in patients undergoing long‐term CRRT for ≥ 7 days.
Akinori Yamaguchi   +6 more
wiley   +1 more source

Thermochemical, spectral and biological activity prediction of some methylpyridine derivatives: a computational approach

open access: yesDiscover Chemistry
Pyridine and its derivatives play a vital role in pharmaceutical and pesticide applications. However, prolonged exposure to pyridine can lead to significant health risks due to its ability to enter the body via inhalation and absorption.
Md. Arifur Rahman   +8 more
doaj   +1 more source

Taking stock: A decade of drug policy - A civil society shadow report. [PDF]

open access: yes, 2018
Taking stock: A decade of drug policy’ evaluates the impacts of drug policies implemented across the world over the past decade, using data from the United Nations (UN), complemented with peer-reviewed academic research and grey literature reports from ...

core  

Synthesis and Antiviral Evaluation of New N-acylhydrazones Containing Glycine Residue

open access: yes, 2011
N-acylhydrazones containing glycine residue 3a-j and 8a-h were synthesized as HIV-1 capsid protein assembly inhibitors. The structures of the novel N-acylhydrazone derivatives were characterized using different spectroscopic methods.
He, Meizi   +15 more
core   +1 more source

Emerging paradigms in anti-infective drug design. [PDF]

open access: yes, 2014
The need for new drugs to treat microbial infections is pressing. The great progress made in the middle part of the twentieth Century was followed by a period of relative inactivity as the medical needs relating to infectious disease in the wealthier ...
Croft, Simon L   +3 more
core   +1 more source

DrugEx v3: Scaffold-Constrained Drug Design with Graph Transformer-based Reinforcement Learning

open access: yes, 2021
Due to the large drug-like chemical space available to search for feasible drug-like molecules, rational drug design often starts from specific scaffolds to which side chains/substituents are added or modified. With the rapid growth of the application of
Adriaan P. , IJzerman   +4 more
core   +1 more source

Organoids in pediatric cancer research

open access: yesFEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Structure-Activity Relationships (SAR) Research of Thiourea Derivatives as Dual Inhibitors Targeting both HIV-1 Capsid and Human Cyclophilin A

open access: yes, 2010
HIV-1 capsid (CA) and human cyclophilin A (CypA) play important roles in HIV-1 assembly and disassembly processes, which are critical in HIV-1 replication.
He, Meizi   +8 more
core   +1 more source

Posterior Segment Ophthalmic Drug Delivery: Role of Muco-Adhesion with a Special Focus on Chitosan

open access: yes, 2021
Posterior segment eye diseases (PSEDs) including age macular degeneration (AMD) and diabetic retinopathy (DR) are amongst the major causes of irreversible blindness worldwide.
Chauhan, Anuj   +17 more
core   +1 more source

Home - About - Disclaimer - Privacy